Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 12/2011

01-12-2011 | Original Paper

The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2011

Login to get access

Abstract

Purpose

Gemcitabine plus cisplatin (GP) is a first-line treatment for advanced non-small-cell lung cancer (NSCLC). In this study, we evaluated the efficacy and safety of a combined treatment consisting of CT-guided percutaneous 125I seed implantation with GP chemotherapy for advanced NSCLC.

Methods

Fifty-three patients with advanced NSCLC were enrolled in a nonrandomized, two-armed clinical trial. Of these patients, 24 received a combination treatment of CT-guided percutaneous 125 I seed implantation and GP (the combo group), while 29 were treated with GP only (the control group).

Results

Patients in the combo group received 125I seed implantation with prescription dose of 100–140 Gy and a total of 55 cycles of GP, and patients in the control group received a total of 73 cycles of GP. The overall response rate was 79.2% in the combo group and 41.4% in the control group. The median overall survival time was 13.5 ± 1.5 months in the combo group and 9.0 ± 1.8 months in the control group. The progression-free survival time was 8.0 ± 1.2 months in the combo group and 5.0 ± 0.8 months in the control group. The 1- and 2-year survival rates were 62.5 and 16.7% in the combo group, respectively, and 41.4 and 13.8% in the control group. The interventional complications in the combo group included 5 cases of pneumothorax and 4 cases of hemoptysis. There were no complications due to radiation pneumonia or radiation esophagitis in the combo group, and no patients had lethal hemoptysis or esophagotracheal fistula. Chemotherapy treatment-related toxicities, including Grade 3/4 myelosuppression and Grade 3 gastrointestinal toxicity, were similar in both groups.

Conclusions

Our initial experience showed that combined CT-guided 125I radioactive seed implantation and GP chemotherapy are effective and safe for treating advanced NCSLC.
Literature
Blanco R, Sole J, Montesinos J, Mesia C, Algara M, Terrassa J, Gay M, Domenech M, Bastus R, Bover I, Nogue M, Vadell C (2008) Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study. Lung Cancer 62:62–71PubMedCrossRef
Brach B, Buhler C, Hayman MH, Joyner LR Jr, Liprie SF (1994) Percutaneous computed tomography-guided fine needle brachytherapy of pulmonary malignancies. Chest 106:268–274PubMedCrossRef
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef
Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol 17:3522–3530PubMed
Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005) International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117:294–299PubMedCrossRef
Ebara S, Katayama N, Tanimoto R, Edamura K, Nose H, Manabe D, Kobayashi T, Kobayashi Y, Kobuke M, Takemoto M, Saika T, Nasu Y, Kanazawa S, Kumon H (2008) Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. Acta Med Okayama 62:9–13PubMed
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMed
Heelan RT, Hilaris BS, Anderson LL, Nori D, Martini N, Watson RC, Caravelli JF, Linares LA (1987) Lung tumors: percutaneous implantation of I-125 sources with CT treatment planning. Radiology 164:735–740PubMed
Hilaris BS, Mastoras DA (1998) Contemporary brachytherapy approaches in non-small-cell lung cancer. J Surg Oncol 69:258–264PubMedCrossRef
Huang K, Sneed PK, Kunwar S, Kragten A, Larson DA, Berger MS, Chan A, Pouliot J, McDermott MW (2009) Surgical resection and permanent iodine-125 brachytherapy for brain metastases. J Neurooncol 91:83–93PubMedCrossRef
Johnson M, Colonias A, Parda D, Trombetta M, Gayou O, Reitz B, Miften M (2007) Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage I non-small cell lung cancer. Phys Med Biol 52:1237–1245PubMedCrossRef
Ke Q, Fu G, Bian Y, Jiang D, Yang J (2009) Concurrent gemcitabine and cisplatin combined with 3D conformal radiotherapy for stage III non-small cell lung cancer. Chin-Ger J Clin Oncol 8:156–159CrossRef
Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, Negoro S, Ariyoshi Y, Nakagawa K, Fukuoka M (2004) The four-arm cooperative study(FACS) for advanced non-small-cell lung cancer(NSCLC). J Clin Oncol 22:7006
Lee W, Daly BD, DiPetrillo TA, Morelli DM, Neuschatz AC, Morr J, Rivard MJ (2003) Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg 75:237–242 discussion 42–43PubMedCrossRef
Martinez-Monge R, Pagola M, Vivas I, Lopez-Picazo JM (2008) CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). Lung Cancer 61:209–213PubMedCrossRef
McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B (2009) Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 73:112–118PubMedCrossRef
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef
Nag S, DeHaan M, Scruggs G, Mayr N, Martin EW (2006) Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 64:736–744PubMedCrossRef
Ning X, Fan X, Yao B, Wang Z (2005) Gemcitabine combined with 125I seed implantation in the treatment of aged non-small cell lung cancer. Chin J Clin Oncol Rehabil 12:83–84
Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98:1–14PubMedCrossRef
Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, Hommura F, Oizumi S, Nishimura M, Shirato H (2008) Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 70:374–381PubMedCrossRef
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2:S94–S100PubMedCrossRef
Peters N, Wieners G, Pech M, Hengst S, Ruhl R, Streitparth F, Lopez Hanninen E, Felix R, Wust P, Ricke J (2008) CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol 184:296–301PubMedCrossRef
Ricke J, Wust P, Wieners G, Hengst S, Pech M, Lopez Hanninen E, Felix R (2005) CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest 127:2237–2242PubMedCrossRef
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef
Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R (2003) Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Strahlenther Onkol 179:823–831PubMedCrossRef
Speiser BL (1999) Brachytherapy in the treatment of thoracic tumors. Lung and esophageal. Hematol Oncol Clin North Am 13:609–634PubMedCrossRef
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
Tian L, Tian R (2008) Clinical efficacy of 125I seed brachytherapy combined with chemotherapy in the treatment 52 cases of advanced lung cancer. Chin J Clin Oncol 35:82–84
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833–4839PubMedCrossRef
Trombetta MG, Colonias A, Makishi D, Keenan R, Werts ED, Landreneau R, Parda DS (2008) Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy in cancer of the lung. Brachytherapy 7:50–54PubMedCrossRef
Trovo MG, Minatel E, Franchin G, Gobitti C, Roncadin M, De Paoli A, Arcicasa M, Boz G, Bortolus R (1992) Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. Radiother Oncol 23:241–244PubMedCrossRef
Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, Ackermann H, Zamboglou N (2011) Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol 6:545–552PubMedCrossRef
Vokes EE, Choy H, Gandara D, Mattson K (2002) Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer 38(Suppl 4):29–35PubMedCrossRef
Zhang FJ, Li CX, Wu PH, Wu YX, Jiao DC, Liu J, Li YL (2007) CT guided radioactive 125I seed implantation in treating localized advanced pulmonary carcinoma. Zhonghua Yi Xue Za Zhi 87:3272–3275PubMed
Zheng G, Chai S, Mao Y, Yan W, Yang J, Liang J (2008) Short-term efficacy of interstitial implantation of 125I seeds combined with chemotherapy for advanced lung cancer. Chin J Minim Invasive Surg 8:122–124
Metadata
Title
The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer
Publication date
01-12-2011
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1048-3

Other articles of this Issue 12/2011

Journal of Cancer Research and Clinical Oncology 12/2011 Go to the issue

Review

BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Original Paper

Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells

Original Paper

Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis

Original Paper

The relationship among PDX1, CDX2, and mucin profiles in gastric carcinomas; correlations with clinicopathologic parameters

Original Paper

Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer

Original Paper

Safety study of axillary reverse mapping in the surgical treatment for breast cancer patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits